Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
Appili to present update on topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX